Stem Cell Therapy Moves to Reinvent Itself, Raise Value
BioWorld Insight Contributing Writer
After seeing its clinical program stall following the failure of a Phase IIb trial testing NTx-265 in acute stroke, Stem Cell Therapeutics Corp. is reinventing itself. (See BioWorld Today, May 26, 2010.)
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST